| Mr Michael Aldred Blackwell Iii, MD | |
|
408 8th St, Suite 4, N Wilkesboro, NC 28659-4167 | |
| (336) 667-7171 | |
| (336) 667-1095 |
| Full Name | Mr Michael Aldred Blackwell Iii |
|---|---|
| Gender | Male |
| Speciality | Obstetrics & Gynecology |
| Location | 408 8th St, N Wilkesboro, North Carolina |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245201573 | NPI | - | NPPES |
| 0297M | Other | NC | BCBS |
| 07-07548 | Other | NC | UNITED HEALTHCARE |
| 89-0297M | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 9500290 (North Carolina) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mr Michael Aldred Blackwell Iii, MD 408 8th St, Suite 4, N Wilkesboro, NC 28659-4167 Ph: (336) 667-7171 | Mr Michael Aldred Blackwell Iii, MD 408 8th St, Suite 4, N Wilkesboro, NC 28659-4167 Ph: (336) 667-7171 |
News Archive
Dr. Joseph Glavy at Stevens Institute of Technology studies the smallest and most basic elements of life. The Assistant Professor of Chemical Biology runs the Glavy Lab, where advanced student scientists study the nuclear pore complexes (NPCs) in cells, observing the minutest mechanisms of life as they unfold during mitosis. The Glavy Lab's formal purpose is to study the NPC at the molecular level in the pursuit of the unknown or unexpected in the well-studied but not always well-understood nuclei of living cells.
According to a new study by researchers in the U.S., oral contraceptives and intrauterine devices (IUD) appear to provide long-term protection against endometrial cancer.
One key problem with treating people with Alzheimer's disease (AD) is the fact that it is often very difficult to detect the disease when it is in the early stages of progression. A team of researchers from the University of the West of England are about to embark on a preliminary study to investigate the efficacy of combining biomarkers in blood with cognitive testing as a way of screening for AD early on so that appropriate treatments can be offered to patients sooner.
Sun Pharmaceutical Industries Ltd. today announced that the United States District Court for the Southern District of New York had dismissed in its entirety the complaint filed by Taro Pharmaceutical Industries Ltd. seeking to block the Tender Offer by Sun's subsidiary, Alkaloida Chemical Company Exclusive Group Ltd., to purchase all outstanding Ordinary Shares of Taro.
Repros Therapeutics Inc. today announced that the Company has received positive written feedback from the FDA (the "Agency") regarding the Company's drug candidate Androxal. The Agency concurred with Repros' indication statement for the use of Androxal in the treatment of secondary hypogonadism in men wishing to preserve fertility.
› Verified 5 days ago